Melanogenesis detection method using FAM86A
The present invention relates to a melanogenesis detection method using FAM86A, and the like. The level of FAM86A of the present invention decreases according to an increase in the amount of melanin secretion or formation, and thus the present invention can whiten the skin by using protein FAM86A or an agonist thereof, and can prevent, treat or alleviate melanin-deficiency diseases such as vitiligo since the formation and secretion of melanin is promoted when FAM86A is inhibited. Therefore, the present invention is expected to be used in various ways, such as a composition for skin whitening using protein FAM86A or an agonist thereof, and as a composition for preventing and treating melanin deficiency diseases including vitiligo and canities by using a FAM86A inhibitor.
1 . A method of treating a melanin-deficient disease in a subject, comprising administering a pharmaceutically effective amount of composition comprising an FAM86A inhibitor as an active ingredient into the subject,
wherein the FAM86A inhibitor is an FAM86A expression inhibitor,
wherein the FAM86A expression inhibitor is an shRNA that complementarily binds to a mRNA of the FAM86A gene, and
wherein the melanin-deficient disease is selected from the group consisting of: leukoderma; vitiligo; quadrichrome vitiligo; vitiligo ponctue; syndromic albinism; Alezzandrini syndrome; Hermansky-Pudlak syndrome; Chediak-Higashi syndrome; Griscelli syndrome type 1/Elejalde syndrome; Griscelli syndrome type 2; Griscelli syndrome type 3; Waardenburg syndrome; Tietz syndrome; CrossMuKusick-Breen syndrome; ABCD syndrome; Albinism-deafness syndrome; Vogt-Koyanagi-Harada syndrome; oculocutaneous albinism; canities; hypomelanosis; idiopathic guttate hypomelanosis; phylloid hypomelanosis; progressive macular hypomelanosis; piebaldism; nevus depigmentosus; postinflammatory hypopigmentation; pityriasis alba; Vagabond's leukomelanoderma; Yemenite deaf-blind hypopigmentation syndrome; Wende-Bauckus syndrome; Woronoff's ring; amelanism; and leucism.
2 . A method of promoting melanogenesis, comprising administering a pharmaceutically effective amount of composition comprising an FAM86A inhibitor as an active ingredient into a subject,
wherein the FAM86A inhibitor is an FAM86A expression inhibitor,
wherein the FAM86A expression inhibitor is an shRNA that complementarily binds to the mRNA of the FAM86A gene, and
wherein the administering increases melanogenesis in the subject.
3 . A method of promoting black hair induction, comprising administering a pharmaceutically effective amount of composition comprising an FAM86A inhibitor as an active ingredient into a subject,
wherein the FAM86A inhibitor is an FAM86A expression inhibitor,
wherein the FAM86A expression inhibitor is an shRNA that complementarily binds to the mRNA of the FAM86A gene, and
wherein the administering promotes the generation of black hair in the subject.